These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4040357)

  • 1. Plasminogen activator activity levels in patients with Behçet's syndrome.
    Mishima H; Masuda K; Shimada S; Toki N; Tsushima H; Gocho M
    Arch Ophthalmol; 1985 Jul; 103(7):935-6. PubMed ID: 4040357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms.
    Aitchison R; Chu P; Cater DR; Harris RJ; Powell RJ
    Ann Rheum Dis; 1989 Jul; 48(7):590-3. PubMed ID: 2505697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiactivator in plasma of patients with Behçet's disease.
    Tsushima H; Toki N
    J Dermatol; 1981 Oct; 8(5):379-83. PubMed ID: 6173406
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of the fibrinolytic system in Behçet's disease?
    Asbeck F; Meyer-Boernecke D; van de Loo J
    Haemostasis; 1977; 6(5):303-9. PubMed ID: 598751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity.
    Saylam Kurtipek G; Kesli R; Tuncez Akyurek F; Akyurek F; Ataseven A; Terzi Y
    Int J Rheum Dis; 2018 Apr; 21(4):866-870. PubMed ID: 27171829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the blood fibrinolytic enzyme system of patients with cutaneous vasculitis.
    Toki N; Yamura T
    Br J Dermatol; 1980 Jul; 103(1):41-50. PubMed ID: 6775670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation and fibrinolytic activity in Behçet's disease.
    Hampton KK; Chamberlain MA; Menon DK; Davies JA
    Thromb Haemost; 1991 Sep; 66(3):292-4. PubMed ID: 1745999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of circulating intercellular adhesion molecule-1 in patients with Behçet's disease.
    Saglam K; Yilmaz MI; Saglam A; Ulgey M; Bulucu F; Baykal Y
    Rheumatol Int; 2002 Jan; 21(4):146-8. PubMed ID: 11843169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for an endothelial cell dysfunction in association with Behçet's disease.
    Schmitz-Huebner U; Knop J
    Thromb Res; 1984 May; 34(4):277-85. PubMed ID: 6429888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous fibrinolytic potential, tPA dependent, is reduced in Behçet's disease.
    Lotti T; Matucci-Cerinic M
    Br J Dermatol; 1989 Dec; 121(6):713-6. PubMed ID: 2514783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase plasminogen activator receptor levels in Behcet's disease.
    Birengel S; Yalçındağ FN; Yalçındağ A; Sahli E; Batıoğlu F
    Thromb Res; 2011 Sep; 128(3):274-6. PubMed ID: 21470667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parameters of hemostasis in Behçet's disease].
    Dupuy E; Tobelem G; Bourgeois P; Soria C; Pellerin A; Bellucci S; Caen JP
    Rev Med Interne; 1983 Dec; 4(4):317-21. PubMed ID: 6665348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The amidolytic activity of the SK-plasminogen complex is enhanced by a potentiator which is generated in the presence of vascular plasminogen activator--role of fibrin degradation products.
    Soria J; Soria C; Bertrand O; Dunn F; Samama M; Bachmann F
    Thromb Haemost; 1982 Jun; 47(3):193-6. PubMed ID: 7051407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemostasis in patients with Behçet's disease.
    Demirer S; Sengül N; Yerdel MA; Tüzüner A; Ulus AT; Gürler A; Bergqvist D; Siegbahn A; Karacagil S
    Eur J Vasc Endovasc Surg; 2000 Jun; 19(6):570-4. PubMed ID: 10873722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.
    Espinosa G; Font J; Tàssies D; Vidaller A; Deulofeu R; López-Soto A; Cervera R; Ordinas A; Ingelmo M; Reverter JC
    Am J Med; 2002 Jan; 112(1):37-43. PubMed ID: 11812405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease.
    Orem A; Değer O; Memiş O; Bahadir S; Ovali E; Cimşit G
    Ann Rheum Dis; 1995 Sep; 54(9):726-9. PubMed ID: 7495343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma osteopontin levels in patients with Behcet's disease and psoriasis.
    Erturkler E; Cıcek D; Kaman D; Ozdogan S; Bakar Dertlıoglu S
    Eur J Dermatol; 2011; 21(2):203-8. PubMed ID: 21489910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do hemorheological alterations play any role in the development of thrombotic events in Behçet's disease?
    Vayá A; Ricart J; Todolí J; Micó L; Contreras T; Aznar J
    Clin Hemorheol Microcirc; 2004; 30(3-4):411-4. PubMed ID: 15258375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced erythrocyte deformability in active and untreated Behçet's disease patients.
    Tatlican S; Duran FS; Eren C; Eskioglu F; Dikmenoglu N; Oktay B; Durmazlar SP; Canpolat F
    Int J Dermatol; 2010 Feb; 49(2):167-71. PubMed ID: 20465640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma thrombomodulin levels in patients with Behçet's disease.
    Düzgün N; Ayaşlioğlu E; Tutkak H; Sahin M; Aydintuğ O; Olmez U
    Rheumatol Int; 2003 May; 23(3):130-3. PubMed ID: 12739044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.